Helix BioPharma Corp. (TSX: HBP, OTC PINK: HBPCF, Frankfurt: HBP0), a clinical-stage oncology company developing therapies for difficult-to-treat cancers, has announced the appointment of Markus Loeffler, MD, MBA, as Chief Medical Officer (CMO). The move comes as the company prepares for a more execution-focused phase of clinical development, with several programs approaching key regulatory and clinical milestones.
Dr. Loeffler will lead the strategy and execution of Helix's clinical programs, including the planned Phase Ib/II evaluation of L-DOS47 in combination with pembrolizumab in first-line non-small cell lung cancer (NSCLC). He will also guide LEUMUNA™ toward clinical development for leukemia relapse following allogeneic stem cell transplantation. This appointment is critical as Helix aims to advance its pipeline and deliver new treatment options for patients with difficult-to-treat cancers.
Thomas Mehrling, MD, PhD, Chief Executive Officer of Helix, expressed confidence in Dr. Loeffler's abilities, stating, "I’ve had the privilege of working with Markus before, and I have seen firsthand his ability to translate innovative science into well-executed clinical development programs. He is an outstanding clinical development leader with a strong track record of advancing innovative oncology therapies through the development pathway. His expertise will be instrumental as we advance L-DOS47 into its next stage of clinical development and prepare LEUMUNA to enter the clinic."
Dr. Loeffler brings more than three decades of leadership in oncology drug development, having held senior roles at Roche, Advanced Accelerator Applications, Mundipharma, NH TherAguix, Corbus Pharmaceuticals, and SK Life Science. He has extensive experience advancing oncology therapeutics, including small molecules, biologics, antibody-drug conjugates (ADCs), radiopharmaceuticals, and immunotherapies, from early clinical development through Phase III and regulatory approval. Notably, he led the pivotal Phase III clinical program for Lutathera®, which was subsequently approved for the treatment of certain gastroenteropancreatic neuroendocrine tumors.
In response to his appointment, Dr. Loeffler said, "I’m excited to join Helix at such an important stage in its evolution. The Company’s pipeline combines strong scientific foundations with clear clinical development opportunities. I am particularly enthused by the opportunity to advance L-DOS47 in combination with checkpoint inhibition and to bring LEUMUNA toward its first clinical evaluation. I look forward to working alongside the team to translate these programs into meaningful new treatment options for patients with difficult-to-treat cancers."
The appointment of Dr. Loeffler is a strategic move for Helix as it seeks to accelerate its clinical development efforts. The company's lead candidate, L-DOS47, is an antibody-enzyme conjugate being developed as a combination therapy for NSCLC. The planned Phase Ib/II trial will evaluate L-DOS47 in combination with pembrolizumab, a checkpoint inhibitor, in the first-line setting. This combination approach is aimed at improving outcomes for patients with NSCLC, a cancer that remains challenging to treat despite advances in immunotherapy.
Additionally, LEUMUNA™, a pre-IND oral immune checkpoint modulator, is being developed for leukemia relapse following allogeneic stem cell transplantation. This is an area of high unmet medical need, as relapse after transplant is associated with poor prognosis. With Dr. Loeffler's guidance, Helix aims to move LEUMUNA into clinical trials, potentially offering a new therapeutic option for these patients.
Helix BioPharma's pipeline also includes GEMCEDA™, a pre-IND gemcitabine prodrug for advanced solid tumors. The company is focused on developing therapies for underserved patient populations with difficult-to-treat cancers.
For more information about Helix BioPharma and its pipeline, visit https://www.helixbiopharma.com/.
